Abstracts tagged "Adverse events"

Abstract Number: 2128 • 2017 ACR/ARHP Annual Meeting
A Systematic Review of the Management of Patients with Preexisting Rheumatologic Diseases Receiving Checkpoint Inhibitors for Cancer
Noha Abdel-Wahab^1,2, Mohsin Shah¹, Maria A. Lopez-Olivo¹ and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Assiut, Egypt
Background/Purpose: The incidence and management of rheumatologic immune-related adverse events (irAEs) as a consequence of the checkpoint inhibitor (CPI) therapy in patients with cancer has…
Abstract Number: 2155 • 2017 ACR/ARHP Annual Meeting
Myositis As a Complication of Checkpoint Blockade at a Comprehensive Cancer Center
Mohsin Shah¹, Jean Tayar¹, Noha Abdel-Wahab^1,2 and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Assiut, Egypt
Background/Purpose: Immune checkpoint inhibitor therapy (ICI) has surfaced as a successful and robust treatment option in the fight to end cancer. As we gain more…
Abstract Number: 2222 • 2017 ACR/ARHP Annual Meeting
Comparative Risk of Respiratory Depression in Patients Treated with Opioids for Non-Malignant Pain
Meghna Jani, Kamilla Kopec-Harding, Mark Lunt and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Opioid use for non-cancer pain has increased considerably over the last 30 years. The U.S. Food and Drug Administration announced several boxed warnings in…
Abstract Number: 2256 • 2017 ACR/ARHP Annual Meeting
Temporal Increases in Side Effect Concerns of Osteoporosis Medications Among Women with Previous Fractures
Maria I. Danila¹, Elizabeth J. Rahn², Amy S. Mudano¹, Ryan Outman³, Peng Li⁴, David T. Redden⁴, Fred A. Anderson⁵, Susan L. Greenspan⁶, Andrea Z. LaCroix⁷, Jeri W. Nieves⁸, Stuart L. Silverman⁹, E.S. Siris¹⁰, Nelson B. Watts¹¹, Sigrid Ladores¹², Karen Meneses¹², Jeffrey R. Curtis¹³ and Kenneth Saag¹³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Medicine, University of Pittsburgh, Pittsburgh, PA, ⁷Group Health Cooperative, Seattle, WA, ⁸Helen Hayes, West Haverstraw, NY, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Columbia University Medical Center, New York, NY, ¹¹University of Cincinnati, Cincinnati, OH, ¹²Nursing, University of Alabama at Birmingham, Birmingham, AL, ¹³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: High-consequence, albeit rare, adverse side effects of osteoporosis medication raise patients’ risk perceptions and contribute to non-adherence. In the past decade, fears of osteonecrosis…
Abstract Number: 2320 • 2017 ACR/ARHP Annual Meeting
Pediatric Rheumatology Infusion Center: Report on Therapeutic Protocols and Infusion Reactions over 4 Years
Annelle Reed¹, Surabhi S. Vinod², Jamelle Maxwell³, Esraa M. A. Eloseily^4,5, Matthew L. Stoll⁴ and Randy Q. Cron⁴, ¹Pediatric rheumatology, Childrens of Alabama, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Childrens of Alabama, Birmingham, AL, ⁴Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, Assiut University, Assiut, Egypt
Background/Purpose: The goals of this report are to describe various therapeutic protocols, volume of intravenous (IV) infusions, and associated adverse events at the University of…
Abstract Number: 527 • 2017 ACR/ARHP Annual Meeting
Cardiovascular Safety of Tocilizumab Versus Abatacept in Patients with Rheumatoid Arthritis: A Multi-Database Study
Seoyoung C. Kim¹, Daniel H. Solomon¹, James R. Rogers², Sara Gale³, Micki Klearman³, Khaled Sarsour³ and Sebastian Schneeweiss², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Genentech, South San Francisco, CA
Background/Purpose: While tocilizumab (TCZ) may increase serum lipid levels, recent studies do not suggest an increased cardiovascular (CV) risk associated with TCZ use compared to…
Abstract Number: 2599 • 2017 ACR/ARHP Annual Meeting
Efficacy and Toxicity of Antimalarials in Systematic Lupus Erythematosus: A Systematic Review
Gaurav Sharma¹, Jasvinder A. Singh², Mohammed Sohaib Khaleel³ and Shristi Shrestha⁴, ¹Department of Medicine, Division of Immunology and Rheumatology, UAB School of Medicine, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Department of Molecular Cardiology, University of Louisville, Louisville, KY, ⁴Internal Medicine, Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal
Background/Purpose: To determine the efficacy and adverse effects of antimalarials in patients with systematic lupus erythematosus (SLE). Methods: A literature search from inception to December…
Abstract Number: 543 • 2017 ACR/ARHP Annual Meeting
Adverse Events in Rheumatoid Arthritis Patients Treated with Disease Modifying Biological Drugs at Hospital Docente Padre Billini in Santo Domingo
I Mercedes-Núñez, E Tejada-Reyes, Y Cruz-Rojas, E Rodríguez-Bautista, R Munoz-Louis, V Rosario, R Peña-Blanco, T Valdez-Lorie and R Alba-Fériz, Rheumatology, Hospital Docente Padre Billini (HDPB), Santo Domingo, Dominican Republic
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune chronic disease with disability and deforms joints. After the introduction of biological therapies the prognosis of…
Abstract Number: 819 • 2017 ACR/ARHP Annual Meeting
Risks of Non-Cardiovascular Corticosteroid Related Adverse Events and Cancer in Giant Cell Arteritis: A French Population-Based Cohort Study
Minh Phuong Do¹, Grégory Pugnet², Guillaume Moulis³, Gregory Guernec⁴, Maryse Lapeyre-Mestre⁵ and Laurent Sailler⁶, ¹Faculté de Médecine, Toulouse University, Laboratoire de Pharmacoepidemiologie, Equipe émergente,UMR INSERM 1027, Toulouse, France, ²Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ³Internal Medicine, Toulouse University Hospital, Toulouse, France, ⁴Faculté de Médecine, Toulouse University, UMR INSERM 1027, Toulouse, France, ⁵UMR 1027, INSERM-University of Toulouse, Toulouse, France, ⁶Medecine Interne, CHU Toulouse, Toulouse, France
Background/Purpose: Corticosteroid related adverse events are a main concern in patients suffering from giant cell arteritis. Conflicting results are reported on this topic, recurrent events…
Abstract Number: 121 • 2017 Pediatric Rheumatology Symposium
Safety Of Biological Response Modifiers In Childhood Autoimmune Rheumatic Diseases From A Single North Indian Centre
Sujata Sawhney¹, Abhay Shivpuri² and Manjari Agarwal³, ¹Paediatric rheumatology, Senior Consultant, New Delhi, India, ²Division of Pediatric Rheumatology,Institute of Child Health, Post Doctoral Fellow, New Delhi, India, ³Institute of Child Health, Attending Consultant, New Delhi, India
Background/Purpose: Biologic Response modifiers (BRMs) are sparingly used in India due to: cost & concern of infections. We are a tertiary level centre & have…
Abstract Number: 438 • 2016 ACR/ARHP Annual Meeting
Glucocorticoid Adverse Effects – the Patient Perspective
Rachel Black¹, Susan M. Goodman², Carlee Ruediger³, Susan Lester⁴, Sarah Mackie⁵ and Catherine Hill³, ¹Department of Medicine, The University of Adelaide, Adelaide, Australia, ²Medicine, Hospital for Special Surgery, New York, NY, ³Medicine, The University of Adelaide, Adelaide, Australia, ⁴Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom
Background/Purpose: Glucocorticoid (GC) use and adverse effects (AEs) are prevalent in rheumatic diseases, yet there is no standardized patient-reported outcome measure to assess benefit and…
Abstract Number: 758 • 2016 ACR/ARHP Annual Meeting
Relationship Between Corticosteroids and Adverse Events in SLE –Data from the Clinical Trial Belimumab in Subjects with Systemic Lupus Erythematosus
Sharzad Emamikia¹, Cidem Gentline², Magnus Backheden³, Katerina Chatzidionysiou², Laurent Arnaud⁴ and Ronald F. van Vollenhoven^2,5, ¹Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Department of Learning, Informatics, Management and Ethics, Unit for Medical Statistics, Stockholm, Sweden, ⁴Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Dept. of Medicine, Karolinska institutet, Stockholm, Sweden, ⁵Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Corticosteroids (CSs) are widely used in Systemic Lupus Erythematosus (SLE) patients, but have side-effects when used for prolonged periods of time. Our aim was…
Abstract Number: 1199 • 2016 ACR/ARHP Annual Meeting
A Genome-Wide Association Study of Methotrexate-Pneumonitis in Rheumatoid Arthritis: Results from the Pneumonitis Study Consortium
James Bluett¹, Sally-Ann Owen¹, Jonathan Massey², Darren Plant², Munir Pirmohamed³, Suzanne M.M. Verstappen⁴ and Anne Barton^5,6, ¹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK, Manchester, United Kingdom
Background/Purpose: Methotrexate (MTX) is associated with a rare but potentially life-threatening lung disease, MTX-pneumonitis (MTX-P). MTX-P is an idiosyncratic hypersensitivity reaction to MTX inducing inflammation,…
Abstract Number: 1492 • 2016 ACR/ARHP Annual Meeting
Biomarker-Related Risk for Myocardial Infarction and Serious Infections in Patients with Rheumatoid Arthritis: A Population-Based Study
Jeffrey Curtis¹, Fenglong Xie², Lang Chen² and Huifeng Yun³, ¹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Background/Purpose: Serious infection events (SIE) and myocardial infarction (MI) are among the most concerning adverse events that occur in rheumatoid arthritis (RA) patients. The role…
Abstract Number: 2178 • 2016 ACR/ARHP Annual Meeting
Statin Use and Increased Risk of Musculoskeletal Conditions: A Retrospective Cohort Study with Propensity Score-Matching
Una E. Makris^1,2, Carlos A. Alvarez^2,3,4, Eric M. Mortensen^2,4 and Ishak Mansi^2,4, ¹Rheumatology, UT Southwestern Medical Center, Dallas, TX, ²VA North Texas Health Care System, Dallas, TX, ³Texas Tech University Health Science Center, Dallas, TX, ⁴UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Given conflicting evidence regarding statin use and the relationship with musculoskeletal conditions, and the rising disability and societal/personal repercussions associated with both osteoarthritis (OA)…

« Previous Page
1
…
3
4
5
6
7
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].